Ignite Creation Date:
2025-12-24 @ 3:14 PM
Ignite Modification Date:
2026-01-12 @ 10:48 PM
Study NCT ID:
NCT01909492
Status:
COMPLETED
Last Update Posted:
2025-06-22
First Post:
2013-07-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
Sponsor:
Providence Health & Services
Organization:
Study Overview
Official Title:
Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2025-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
Detailed Description:
The goal of this study is to obtain baseline information on serum and cerebrospinal fluid (CSF) relaxin levels in patients with MS, as well as to further study RXFP-1 receptor binding affinity for RLX in patients with active and clinically stable MS.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: